Article Type
Changed
Thu, 12/15/2022 - 17:56

Higher protein intake, particularly protein from animal sources, is associated with a modest but lower risk of breast cancer recurrence and death, regardless of insulin receptor status.

Using information gathered through biennial questionnaires from 6,348 women who were diagnosed with stage I to III breast cancer between 1976 and 2004, investigators found a significant inverse association between total protein intake and distant breast cancer recurrence (P = .02). This association was driven specifically by protein from animal sources (P = .003) rather than vegetable sources.

camij/thinkstock
Furthermore, the 5-year recurrence-free survival for women in the highest quintile of protein consumption was 94.0%, while those in the lowest quintile of protein consumption, had 5-year recurrence-free survival of 92.1%. Similarly, the corresponding 10-year recurrence-free survival rates were 87.4% and 83.3%, respectively, reported Michelle Holmes, MD, of Brigham and Women’s Hospital, Boston, and her associates (J Clin Oncol. 2016 Nov 7. doi: 10.1200/JCO.2016.68.3292).

Pathology records were reviewed and histology samples were analyzed for insulin receptor and estrogen receptor expression. Associations between breast cancer recurrence and protein intake, amino acids, or protein-containing food groups did not differ by tumor receptor status or body mass index at time of cancer diagnosis. Given that the association between protein intake and recurrence was not confined to tumors expressing insulin receptors, “It is difficult to invoke the insulin pathway as a mechanism to explain these findings,” the investigators wrote.

Given the only “modest survival advantage” of higher protein intake among women with breast cancer, and given the “challenges involved in randomized trials of diet, this association is unlikely to ever be definitively tested in a randomized trial,” Dr. Holmes and her associates wrote.

“However, the modest survival advantage with higher protein intake has been found in several studies, and we feel it is important that patients with breast cancer and their clinicians know this. At the least, it may provide reassurance that consuming protein-containing foods is not likely to increase the risk of breast cancer recurrence,” the researchers concluded.

This study was sponsored by grants from the National Institutes of Health. Dr. Holmes and one other investigator reported receiving financial compensation from Bayer HealthCare Pharmaceuticals.

Publications
Topics
Sections

Higher protein intake, particularly protein from animal sources, is associated with a modest but lower risk of breast cancer recurrence and death, regardless of insulin receptor status.

Using information gathered through biennial questionnaires from 6,348 women who were diagnosed with stage I to III breast cancer between 1976 and 2004, investigators found a significant inverse association between total protein intake and distant breast cancer recurrence (P = .02). This association was driven specifically by protein from animal sources (P = .003) rather than vegetable sources.

camij/thinkstock
Furthermore, the 5-year recurrence-free survival for women in the highest quintile of protein consumption was 94.0%, while those in the lowest quintile of protein consumption, had 5-year recurrence-free survival of 92.1%. Similarly, the corresponding 10-year recurrence-free survival rates were 87.4% and 83.3%, respectively, reported Michelle Holmes, MD, of Brigham and Women’s Hospital, Boston, and her associates (J Clin Oncol. 2016 Nov 7. doi: 10.1200/JCO.2016.68.3292).

Pathology records were reviewed and histology samples were analyzed for insulin receptor and estrogen receptor expression. Associations between breast cancer recurrence and protein intake, amino acids, or protein-containing food groups did not differ by tumor receptor status or body mass index at time of cancer diagnosis. Given that the association between protein intake and recurrence was not confined to tumors expressing insulin receptors, “It is difficult to invoke the insulin pathway as a mechanism to explain these findings,” the investigators wrote.

Given the only “modest survival advantage” of higher protein intake among women with breast cancer, and given the “challenges involved in randomized trials of diet, this association is unlikely to ever be definitively tested in a randomized trial,” Dr. Holmes and her associates wrote.

“However, the modest survival advantage with higher protein intake has been found in several studies, and we feel it is important that patients with breast cancer and their clinicians know this. At the least, it may provide reassurance that consuming protein-containing foods is not likely to increase the risk of breast cancer recurrence,” the researchers concluded.

This study was sponsored by grants from the National Institutes of Health. Dr. Holmes and one other investigator reported receiving financial compensation from Bayer HealthCare Pharmaceuticals.

Higher protein intake, particularly protein from animal sources, is associated with a modest but lower risk of breast cancer recurrence and death, regardless of insulin receptor status.

Using information gathered through biennial questionnaires from 6,348 women who were diagnosed with stage I to III breast cancer between 1976 and 2004, investigators found a significant inverse association between total protein intake and distant breast cancer recurrence (P = .02). This association was driven specifically by protein from animal sources (P = .003) rather than vegetable sources.

camij/thinkstock
Furthermore, the 5-year recurrence-free survival for women in the highest quintile of protein consumption was 94.0%, while those in the lowest quintile of protein consumption, had 5-year recurrence-free survival of 92.1%. Similarly, the corresponding 10-year recurrence-free survival rates were 87.4% and 83.3%, respectively, reported Michelle Holmes, MD, of Brigham and Women’s Hospital, Boston, and her associates (J Clin Oncol. 2016 Nov 7. doi: 10.1200/JCO.2016.68.3292).

Pathology records were reviewed and histology samples were analyzed for insulin receptor and estrogen receptor expression. Associations between breast cancer recurrence and protein intake, amino acids, or protein-containing food groups did not differ by tumor receptor status or body mass index at time of cancer diagnosis. Given that the association between protein intake and recurrence was not confined to tumors expressing insulin receptors, “It is difficult to invoke the insulin pathway as a mechanism to explain these findings,” the investigators wrote.

Given the only “modest survival advantage” of higher protein intake among women with breast cancer, and given the “challenges involved in randomized trials of diet, this association is unlikely to ever be definitively tested in a randomized trial,” Dr. Holmes and her associates wrote.

“However, the modest survival advantage with higher protein intake has been found in several studies, and we feel it is important that patients with breast cancer and their clinicians know this. At the least, it may provide reassurance that consuming protein-containing foods is not likely to increase the risk of breast cancer recurrence,” the researchers concluded.

This study was sponsored by grants from the National Institutes of Health. Dr. Holmes and one other investigator reported receiving financial compensation from Bayer HealthCare Pharmaceuticals.

Publications
Publications
Topics
Article Type
Click for Credit Status
Ready
Sections
Article Source

FROM THE JOURNAL OF CLINICAL ONCOLOGY

Disallow All Ads
Vitals

Key clinical point: Higher intake of protein, particularly protein from animal sources, is associated with lower risk of breast cancer death and tumor recurrence.

Major finding: The 5-year recurrence-free survival for women in the highest quintile of protein consumption was 94.0%, while those in the lowest quintile of protein consumption had 5-year recurrence-free survival of 92.1%.

Data source: Biennial questionnaires for 6,348 women diagnosed with any stage breast cancer between 1976 and 2004.

Disclosures: This study was sponsored by grants from the National Institutes of Health. Dr. Holmes and one coinvestigator reported receiving financial compensation from Bayer HealthCare Pharmaceuticals.